As a patient with Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) or family member, this News Update page will help keep you up to date with current news about NASH.
May 13, 2021
This study looked at the prevalence and risk factors for MAFLD (metabolic associated fatty liver disease in a population of Chinese patients who were diagnosed with nonalcoholic fatty liver disease.
They examined 139,700 patients and found a MAFLD prevalence rate of 26.1% and that those who were overweight, as defined by their BMI had a MAFLD prevalence rate of 27.4% and if defined as obese, 59.8%. Many other risk factors were also studied and results shared in this study.
The paper does make the claim that the term NAFLD has been replaced with MAFLD. "Metabolic associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a new definition of liver disease associated with known metabolic dysfunction and is the most common chronic liver disease worldwide."
The link to the original paper is: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-021-01782-w
March 30, 2021
News Medical Life Sciences
“NAFLD affects more than 1-in-10 children in the U.S. and now is the nation's most common chronic liver disease within this population. The disease can lead to nonalcoholic steatohepatitis (NASH), a chronic condition that can lead to serious illness, liver transplants, and death. Risk factors include obesity and family history.” "In this review, researchers focused on studies that linked excessive fructose intake to children with NAFLD, interventions that restricted fructose, and identification of related metabolic biomarkers."
March 25, 2021
Financial Post
“The data presented at ENDO 2021 highlights tesamorelin’s unique mechanism of action that addresses the underlying cause of liver disease and further supports the Phase 3 development of this novel medicine for the potential treatment of NASH,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer at Theratechnologies.”
March 19, 2021
BioSpace
“Gilead is pleased to expand our collaboration with Novo Nordisk and advance understanding of the potential for combination approaches in treating people living with cirrhosis due to NASH,” said Mark Genovese, MD, Senior Vice President, Inflammation Clinical Development at Gilead Sciences. “This study is the latest example of our persistent focus on driving innovation to improve the lives of people living with liver diseases and fibrosis.”
February 17, 2021
eatthis.com
"One study suggests drinking just one of the artificially sweetened beverages daily was linked to an 8% higher risk of type 2 diabetes"
https://www.eatthis.com/news-one-major-effect-of-drinking-diet-soda-every-day/
February 12, 2021
Helio Gastroenterology
Can fatty liver patients lose weight and keep it off? Many can be successful, while others struggle and likely could use additional support.
Healio Gastroenterology spoke with Anna S. Lok, MD, professor of internal medicine, director of clinical hepatology, University of Michigan, about results from the ongoing TARGET-NASH study assessing weight loss and weight regain in NAFLD patients.
January 21, 2021
Cancer Health
"Semaglutide, a medication used to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, according to research presented at the at the AASLD virtual Liver Meeting. What’s more, combining semaglutide with other drugs led to greater improvements in various measures of fibrosis, metabolism and liver health."
"In people with NASH, combining semaglutide with cilofexor or firsocostat may provide additional benefits compared with semaglutide alone, Alkhouri and colleagues concluded."
https://www.cancerhealth.com/article/semaglutide-promise-fatty-liver-disease
January 18, 2021
Jerusalem Post
This study which included 382 patients, found that people suffering from Non-alcoholic Fatty Liver Disease (NAFLD) have been found to be roughly three times as likely to die from coronavirus than those who did not suffer from any liver disease, according to a study done at Sheba Medical Center.
January 9, 2021
HepMag – "NAFLD-related liver deaths were most strongly linked to sugar-sweetened drinks and diets low in components of a Mediterranean diet, such as nuts and seeds, as well as impaired kidney function. High consumption of trans fats led to an almost 3% rise in such deaths even after adjusting for metabolic risk factors."
Click here to read the study abstract from The Liver Meeting Digital Experience.
https://www.hepmag.com/article/sugary-drinks-trans-fats-increase-risk-death-fatty-liver-disease
January 3, 2021
Medical Dialogues – Even greater weight loss may lead to further improvements. The meta-analysis study showed a number of weight loss related benefits.
TORONTO, ON, Dec. 17, 2020 – With 25% of Canadians having non-alcoholic fatty liver disease (NAFLD) and 25% of those patients progressing to non-alcoholic steatohepatitis (NASH), there are an estimated 1.5 million Canadians at risk of having liver disease progression to cirrhosis and possible liver transplant.
“Fatty liver disease is a silent killer - often no symptoms are exhibited until the liver is cancerous, and by then it’s often too late,” said Michael Betel, founder of NASHnet.ca. “We were shocked to learn that even though many respondents were obese and had diabetes, only 28% had spoken with their physician about fatty liver disease. However, we were encouraged to see that 95% of those who were members of a Facebook patient support group had reached out to their doctor for important life-saving discussions.”
Today at the Digital 4th NASH Summit, data from a recent study was presented showing that members of a Facebook NASH group were more than twice as likely (94% versus 38-47%) to know what fatty liver disease is.
Patients with fatty liver disease should know that diet and exercise can help improve their liver, yet only 33% of those surveyed did. However, a very impressive 61% who were in a patient support group were aware that diet and exercise could help them.
To learn more about non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and treatments available, please visit NASHnet.ca.
About NASHnet.ca
NASHnet.ca is dedicated to the education and support of fatty liver disease patients and their families. Medical health specialists including hepatologists, gastroenterologists, and nurses share current insights in an innovative Q&A style video response format. With over 25 years of experience in liver world, the site was created and is run by Michael Betel.
FOR MORE INFORMATION:
Email: michael.betel@nashnet.ca
December 15, 2020
Cardiologytoday
“Statins should be first-line therapy in patients with NAFLD, even in most of those for whom it has progressed to nonalcoholic steatohepatitis (NASH)..."
https://www.healio.com/news/cardiology/20201214/many-drug-therapy-options-exist-for-nafld
December 11, 2020
Hep - By Sukanya Charuchandra
“Researchers suggest that 67.3 million people are living with NAFLD in the United States and Canada.” "The team found that the overall estimated prevalence of NAFLD was 23%." "Based on the current population in the United States and Canada, the researchers estimated that 67.3 million people are living with NAFLD, 27.6 million with NASH and 8.7 million with advanced fibrosis."
https://www.hepmag.com/article/nearly-quarter-north-americans-may-fatty-liver-disease
The original abstract is here: https://aasld.confex.com/aasld/2020/meetingapp.cgi/Paper/20191
December 1, 2020
Healio
“Fewer patients had progression of fibrosis, and there were significant improvements in fibrosis biomarkers,” Newsome said. “In addition, there were improvements in multiple metabolic characteristics, and the safety profile was very much consistent with that seen in patients treated with semaglutide with type 2 diabetes.”
November 14, 2020
Global Banking and Finance Review
“We are moving forward with a comprehensive clinical development program designed to build upon the promising results from BIO89-100’s Phase 1b/2a trial, which includes plans to initiate a Phase 2b study in the first half of 2021 and an open-label paired biopsy histology cohort in the near-term. Today’s data are encouraging for these planned studies as we believe they demonstrate BIO89-100’s compelling risk-benefit profile as a leading FGF21 analog in a class that could become a key part of the NASH treatment paradigm,” said Rohan Palekar, Chief Executive Officer, 89bio."
But "unexpected" lack of improvement in fibrosis stage vs placebo
November 14, 2020
MEDPAGE Today
"More patients who received subcutaneous semaglutide (Ozempic), the glucagon-like peptide-1 (GLP-1) receptor agonist, saw resolution of their nonalcoholic steatohepatitis (NASH), with no worsening of fibrosis, versus patients who received placebo in a randomized trial. However, there was no difference in improvement in fibrosis stage between the two groups (43% in the 0.4-mg group vs 33% in placebo group, P=0.48)."
"One possible limitation to the trial was the lack of long-term clinical outcomes."
https://www.medpagetoday.com/meetingcoverage/aasld/89674
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
November 13, 2020
Newswire
In the 100 mg open label arm of MAESTRO-NAFLD:
October 27, 2020
hep
Interesting overview of past and future potential therapies for NASH.
"Linked to obesity and diabetes, NAFLD/NASH is increasingly recognized as a manifestation of metabolic syndrome, characterized by abdominal obesity, high blood pressure, elevated blood sugar and abnormal cholesterol or triglyceride levels."
https://www.hepmag.com/article/pipeline-nafld-nash-treatment
October 25, 2020
hepmag.com
By Sukanya Charuchandra
"Thus lean participants had a lower prevalence of NAFLD cirrhosis, heart disease and metabolic deviation than their non-lean counterparts. Further, lean Asians had even lower prevalence, across all the BMI groups."
https://www.hepmag.com/article/lean-asians-nafld-show-lower-prevalence-cirrhosis-heart-disease
October 14, 2020
Daix (France), Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to lanifibranor, the Company’s lead drug candidate, for the treatment of NASH. Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015.
October 7, 2020
HCPLive
"Physicians should consider integrating non-invasive, point-of-care liver examinations as a way to improve patient intake, outcomes, lower costs and enhance income stream. FibroScan, for example, is an FDA cleared technology for the diagnosis and monitoring of adult patients as part of an overall evaluation of liver health."
Non-Invasive Test to Detect and Monitor for Liver Disease Among Veterans Signals Clinical Trend for All Americans
October 6, 2020
HCPLive
"The Veterans Health Administration (VHA) has implemented several innovative strategies to manage liver disease. This has been illustrated with success in identifying, treating and curing a significant portion of veterans with chronic hepatitis C infection. Now, major efforts are being undertaken to implement an effective population health management strategy for veterans with NAFLD that may present a path forward for the rest of country."
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
October 2, 2020
Madrigal Pharmaceuticals
September 14, 2020
BioSpace
" Theratechnologies Inc.. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the general population."
“After careful review of our file and discussions with our scientific advisers, we made the decision to pursue the Phase 3 development of tesamorelin for the treatment of NASH in the general population,” said Mr. Paul Lévesque, President and Chief Executive Officer, Theratechnologies.'
September 10, 2020
TargetRWE
"As expected, we found that most patients with NAFLD were overweight or obese and only 13% had normal BMI (lean NAFLD). Across all races and ethnicities, NAFLD patients with normal BMI were less likely to have cirrhosis, cardiovascular, or metabolic diseases than those who are obese," said Anna Lok, MD, Professor of Medicine at the University of Michigan, and senior author. "Even so, we need to help NAFLD patients with normal BMI to get rid of the fat in their liver and to understand if their liver, cardiovascular, and metabolic diseases progress at slower rates than those who are obese."
September 8, 2020
HCPLive
"The key message for caregivers is that NAFLD is manageable, and potentially reversible if caught in its early stages. Diet and exercise are the most effective treatments, but poor adherence often makes this a challenge for many people."
August 18, 2020
Science Daily
"A new review suggests that following menopause, women are at higher risk for developing nonalcoholic fatty liver disease (NAFLD), a chronic condition caused by the build-up of excess fat in the liver not caused by alcohol."
https://www.sciencedaily.com/releases/2020/08/200817191747.htm
August 13, 2020
Bio Spectrum
"Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally to treat nonalcoholic steatohepatitis (NASH)."
July 27, 2020
Medical Press
"Currently, most leading therapeutic drugs undergoing clinical trials for NASH are small molecules given as a systemic treatment," Rincon said. "Our data show, in contrast, that the use of siRNA to reduce the levels of MCJ in the liver may constitute an alternative therapeutic strategy." Journal information: Nature Communications
https://medicalxpress.com/news/2020-07-therapy-epidemic-liver-disease.html
July 25, 2020
Medscape
"Women have a lower risk of nonalcoholic fatty liver disease compared with men, but those who do develop the disease are significantly more likely than are men to develop advanced fibrosis, according to data from a meta-analysis of more than 62,000 individuals."
https://www.medscape.com/viewarticle/934059
July 13, 2020
Global News Network
"Doctors are warning that soaring rates of a common, but often undetected, liver disease could impose an enormous burden on Canadian health care over the next decade if there isn’t more public awareness."
https://globalnews.ca/news/7170904/nonalcoholic-fatty-liver-disease-canada-study/
June 29, 2020
Canadian NASH Network
First National Study Predicts an Escalating Epidemic of Nonalcoholic Fatty Liver Disease (NAFLD)
Business Wire via Yahoo Finance!
June 19, 2020
"Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced that it has screened the first patient for the LIFT study, a Phase 2a clinical trial of TERN-101, a liver-selective farnesoid X receptor (FXR) agonist, the company's lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH)."
https://finance.yahoo.com/news/terns-pharmaceuticals-initiates-lift-study-183000553.html
EurekAlert!
June 9, 2020
"Non-alcoholic fatty liver disease (NAFLD) in pregnancy has nearly tripled over the past ten years. It increases risks for both mother and baby, including hypertensive complications of pregnancy, bleeding after delivery, and preterm birth, report investigators in the Journal of Hepatology, published by Elsevier."
https://www.eurekalert.org/pub_releases/2020-06/e-nip060420.php
Texarcana Gazzette
May 31, 2020
"So, should you be screened for NAFLD? Considering how prevalent NAFLD is and how many folks don't know they have it, researchers suggest anyone with visceral abdominal fat — that's fat around your middle — insulin resistance or Type 2 diabetes get screened, initially using ultrasound. If NAFLD shows up, then you should see a hepatologist (liver specialist) for an MRI and treatment."
May 28, 2020
HIT Consultant
Scott Howell, D.O., MPH&TM, CPE, is an advisor for Echosens, The Liver Company.
"The point of non-invasive, painless technology is that these tools can quickly and easily measure the amount of liver stiffness and fat to better target more expensive or more invasive diagnostic procedures – saving time and resources for clinicians by eliminating patients who don’t need additional assessment."
May 22, 2020
Biopharma
"The company said that the agency had requested additional data for obeticholic acid and thus pushed the upcoming advisory committee meeting back from June 9, thereby delaying its decision on approval, which had also been scheduled for June 26."
May 21, 2020
Can-Fite BioPharma Ltd. Press Release
"Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the U.S. Patent and Trademark Office (PTO) has issued a Notice of Allowance for the Company’s patent titled, "Method for treating NASH accompanied by fibrosis using CI-IB-MECA". The allowance follows Can-Fite’s recent announcement of highly encouraging data from its Phase II study of its drug candidate Namodenoson, generically known as CI-IB-MECA, in the treatment of non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH)."
https://finance.yahoo.com/news/fite-receives-notice-allowance-namodenoson-110000312.html
May 11, 2020
Biotech: By ADAM FEUERSTEIN @adamfeuerstein
"French drug maker Genfit said Monday that its lead drug, Elafibranor, failed to improve outcomes for patients with the fatty liver disease NASH, according to an interim analysis of a late-stage clinical trial."
May 9, 2020
FiercePharma
Drug development for non-alcoholic steatohepatitis has witnessed plenty of failures—and plenty of excitement as multiple players race toward market. Now, Novo Nordisk's popular GLP-1 diabetes drug semaglutide has racked up some encouraging clinical results that take it one step closer to the finish line."
https://www.eurekalert.org/pub_releases/2020-05/w-fld050520.phphttps://www.fiercepharma.com/pharma/novo-nordisk-s-diabetes-blockbuster-semaglutide-shows-promise-nash-but-questions-remain
May 6, 2020
"In the Alimentary Pharmacology & Therapeutics analysis of information on 10,826,456 adults, the prevalence of NAFLD was 5.7%. NAFLD progressed to the more serious liver disease called cirrhosis in 39% of patients with NAFLD over 8 years of follow-up. Cardiovascular disease, kidney impairment, high cholesterol, and diabetes were linked with higher risks of disease progression."
https://www.eurekalert.org/pub_releases/2020-05/w-fld050520.php
May 5, 2020
Healio Gastroenterology and Liver Disease
"Fatty liver disease is in 30% of Americans and there is not a quick way to test and a lot of people don’t know about it. We did this test to see how many people we could get with this quick liver determination,” Salem told Healio Gastroenterology and Liver Disease. “We chose the Minnesota State Fair because it has the largest population in the United States for 5 days.”
April 23, 2020
Medical News Today
"By the end of the trial, the inactive mice had fatty liver disease, a precursor of liver cancer, while the other group did not."
"The mice in both groups had obesity and were candidates for diabetes. However, far more of the sedentary mice — 64% compared with 15% — developed liver cancer."
Full published study: https://www.journal-of-hepatology.eu/article/S0168-8278(20)30104-5/fulltext
April 22, 2020
Express.co.uk
"It follows research showing obesity is a bigger risk factor for deadly complications of Covid-19 than heart disease, high blood pressure and diabetes put together in the under-50s."
April 20, 2020
Harvard Health Publishing - Harvard Health Medical School
“Many previous studies have found that people who regularly consume the Mediterranean diet have lower rates of bowel cancer, insulin resistance, fatty liver disease, and other diseases."
April 17, 2020
CancerNetwork
“The most pronounced increase was found in PLC caused by NASH, suggesting that weight management and obesity control deserve more attention in PLC primary prevention schedules, the authors wrote." PLC is Primary Liver Cancer.
April 17, 2020
TheLancet.com: May 2020 Editorial
"Following a survey and Delphi process, the term “metabolic associated fatty liver disease” (MAFLD) was selected to replace NAFLD."
"Substantial momentum will be required to fully adopt the proposed change from NAFLD to MAFLD, and there are worthy arguments to be made that redefining and renaming the disease risks confusing patients and clinicians alike."
https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(20)30091-1.pdf
April 16, 2020
Minnesota Daily
"NASH increases the risk of cardiovascular disease and complications,” said Peter Crawford, review co-author and University professor of medicine. “In fact, the most common cause of death of people with NASH is cardiac disease.” (April 5, 2020)
April 16, 2020
"CONSHOHOCKEN, Pa., April 14, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that in response to guidance from regulatory agencies, measures for COVID-19 at impacted sites have been put in place for its Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 studies, allowing both studies to continue without changes to the protocol. Both MAESTRO studies are well-established and have been recruiting according to plan. At a recently conducted Data Monitoring Committee (DMC) meeting it was recommended that Phase 3 studies proceed without modification."
April 15, 2020
“If the present studies in an animal model that closely resembles humans with fatty liver disease can be replicated in patients, it is likely that exercise could delay the onset of liver cancer and mitigate its severity, if not completely prevent it – thereby greatly improving patient outcomes...”
https://telanganatoday.com/regular-exercise-could-help-prevent-liver-cancer
April 15, 2020
Health Matters: NBC
"While it typically presents with no symptoms—doctors say fatty liver disease can come with some dangerous side effects. “There are associated conditions, such as diabetes, insulin resistance, hyper cholesterol,” said Dr. Archi Ramaswami, a pediatric gastroenterologist with Golisano Children’s Hospital."
https://www.nbc-2.com/story/42000178/health-matters-treating-fatty-liver-disease-in-children
April 13, 2020
Journal of Hepatology
"Patients with NAFLD had higher risk of disease progression, higher likelihood of abnormal liver function from admission to discharge and longer viral shedding time when compared with non-NAFLD subjects."
https://www.journal-of-hepatology.eu/article/S0168-8278(20)30206-3/fulltext
April 11, 2020
NASDAQ site
NASDAQ posted a list of 21 public companies currently researching new drugs for NASH.
"Obesity and type 2 diabetes increase the risk of developing NASH. With the rising prevalence of both obesity and type 2 diabetes, it is only natural that the number of NSAH cases is going to increase. Globally, NASH is prevalent in 10% to 30% of the population."
https://www.nasdaq.com/articles/will-fda-approve-first-nash-drug-in-2020-2020-04-09
April 8, 2020
Can-Fite BioPharma Ltd Press Release
"Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced that its Phase II exploratory NAFLD/NASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile."
April 8, 2020
Can-Fite BioPharma Ltd Press Release
"Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced that its Phase II exploratory NAFLD/NASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile."
April 7, 2020
Digestive Diseases — Kang MK, et al.
"This study was sought to assess whether sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD) in inflammatory bowel disease (IBD) individuals. The results of this study indicate that 11.1% was the prevalence of nonalcoholic fatty liver in IBD patients, and sarcopenia was an independent risk factor."
April 6, 2020
JOSLIN DIABETES CENTER
"...recent research from Dr. Kulkarni's lab at Joslin has uncovered a biomarker in humans tied to the development of NAFLD that might help doctors detect early stages of the disease."
https://www.eurekalert.org/pub_releases/2020-04/jdc-peb040620.php
April 6, 2020
Minnesota Daily
"The researchers published a review last month about the liver disease, called nonalcoholic steatohepatitis (NASH). NASH is initially symptomless and difficult to identify and is commonly found in patients with metabolic disorders like diabetes, obesity and high cholesterol. Researchers said weight loss surgery may be a good treatment for the disorder."
It’s High Time NAFLD Was Renamed, Experts Say
April 5, 2020
"An expert panel has called for renaming non-alcoholic fatty liver disease (NAFLD), preferring the name metabolic-associated fatty liver disease (MAFLD) to better reflect the drivers of the disease and to improve efforts to prevent and treat it."
https://www.hepmag.com/article/high-time-nafld-renamed-experts-say
Organoids for the Development of Drugs and Diagnostics for NASH
April 4, 2020
"Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers."
"Traditionally drug candidates for the disease were tested on animals fed a ‘NASH-inducing diet’; however, researchers suggest this is impractical and so for their study, published in Biomaterials, they harvested cells from the livers of NASH mice at three different stages of the disease and grew them into organoids."
New Diagnostic Methods Needed for NASH Patients
April 3, 2020
“The 3 non-invasive methods we investigated agreed on a NASH diagnosis for only about one-fifth of the participants in the database,” Friedman said in a statement. “These results imply that better methods are needed to predict NASH.”
https://www.mdmag.com/medical-news/new-diagnostic-methods-nash-patients
April 2, 2020
March 23, 2020: Medscape https://www.medscape.com/viewarticle/927374
"The findings come from an analysis of data from the Global Burden of Disease (GBD) Study 2017, published online March 23 in Cancer."
"From 1990 to 2017, the number of cancer cases increased nearly threefold in older men and more than twofold in older women (aged 60 years or more). This increase was driven mainly by an increase in liver cancer caused by nonalcoholic steatohepatitis (NASH), also termed fatty liver disease, note the authors."
Keywords: nonalcoholic fatty liver disease, NASH
This website uses cookies. By continuing to use this site, you accept our use of cookies.